利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.024 秒)

    APTAMER TO FGF2 AND USE THEREOF
    2.
    发明申请
    APTAMER TO FGF2 AND USE THEREOF 失效
    APTAMER至FGF2及其用途

    公开(公告)号：US20130039855A1

    公开(公告)日：2013-02-14

    申请号：US13578023

    申请日：2011-02-10

    申请人： Yoshikazu Nakamura ,  Akira Ishiguro ,  Maiko Sakamoto

    发明人： Yoshikazu Nakamura ,  Akira Ishiguro ,  Maiko Sakamoto

    IPC分类号： C07H21/02 ,  G01N21/64 ,  G01N33/53 ,  C12N9/96 ,  A61K49/00

    CPC分类号： C12N15/115 ,  A61K31/7105 ,  A61K31/712 ,  C12N2310/16 ,  C12N2310/322 ,  C12N2310/344

    摘要： Provided are an aptamer having an inhibitory activity on FGF2; a complex containing an aptamer having a binding activity or an inhibitory activity on FGF2, and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery vehicle, or drug and the like); a medicament, diagnostic reagent or label containing an aptamer having a binding activity or an inhibitory activity on FGF2, or a complex containing said aptamer and a functional substance; and the like.

    摘要翻译： 提供对FGF2具有抑制活性的适体; 含有对FGF2具有结合活性或抑制活性的适体的复合物和功能性物质（例如亲和性物质，标记物质，酶，药物输送载体，药物等）; 包含对FGF2具有结合活性或抑制活性的适体的药物，诊断试剂或标记，或含有所述适体和功能性物质的复合物; 等等。

    METHOD FOR PRODUCING CERIUM-BASED COMPOSITE OXIDE, SOLID OXIDE FUEL CELL, AND FUEL CELL SYSTEM
    6.
    发明申请
    METHOD FOR PRODUCING CERIUM-BASED COMPOSITE OXIDE, SOLID OXIDE FUEL CELL, AND FUEL CELL SYSTEM 审中-公开
    生产基于CERA的氧化复合氧化物，固体氧化物燃料电池和燃料电池系统的方法

    公开(公告)号：US20140308601A1

    公开(公告)日：2014-10-16

    申请号：US14009216

    申请日：2012-03-30

    申请人： Shigeru Ando ,  Akira Ishiguro ,  Akira Kawakami ,  Megumi Shimazu ,  Yutaka Momiyama ,  Yasuo Kakinuma

    发明人： Shigeru Ando ,  Akira Ishiguro ,  Akira Kawakami ,  Megumi Shimazu ,  Yutaka Momiyama ,  Yasuo Kakinuma

    IPC分类号： H01M8/02

    CPC分类号： H01M8/0217 ,  C01F17/0043 ,  C01P2002/52 ,  C01P2002/72 ,  C01P2002/82 ,  C01P2004/82 ,  C01P2006/12 ,  C04B35/50 ,  C04B35/6263 ,  C04B2235/3224 ,  C04B2235/3227 ,  C04B2235/3229 ,  C04B2235/3286 ,  C04B2235/443 ,  C04B2235/5409 ,  H01M4/905 ,  H01M4/9066 ,  H01M8/0202 ,  H01M2008/1293 ,  H01M2300/0071

    摘要： On the other hand, the possibility of estimating the dopant ratio of a metal element to each ceria crystalline particle using integral-width or half-width obtained by XRD was considered as follows: an XRD peak is shifted depending on the dopant ratio of La to ceria; when La increases, an XRD peak is shifted to a lower angle; in XRD performed on a raw material obtained by mixing ceria crystalline particles having different dopant ratio, peaks corresponding to the respective dopant ratio exist close to each other; as a result, a peak width is widened; accordingly, the dopant ratio of a metal element to each ceria crystalline particles are supposed to vary when integral-width and half-width obtained by XRD are large. Thus, it was revealed for the first time that integral-width and half-width obtained by XRD indicate variations in dopant ratio. It should be noted that from the direct proportional relationship between the dopant ratio x and the integral-width for dopant ratio ranging from 0.35 to 0.45, integral-widths obtained by XRD are derived to be 0.10 to 0.30 for dopant ratio ranging from 0.35 to 0.45, and half-widths are derived to be 0.10 to 0.30 similarly.

    摘要翻译： 另一方面，使用通过XRD得到的整体宽度或半宽度来估计金属元素与每个二氧化铈晶粒的掺杂比率的可能性被认为如下：XRD峰值根据La的掺杂剂比率而偏移 二氧化铈 当La增加时，XRD峰移动到较低的角度; 在通过混合具有不同掺杂剂比率的二氧化铈晶粒获得的原料进行的XRD中，与各自的掺杂剂比例相对应的峰彼此接近; 结果，峰宽变宽; 因此，当通过XRD获得的整体宽度和半值宽度时，假定金属元素与每种二氧化铈晶体颗粒的掺杂比变化。 因此，首次揭示了通过XRD获得的积分宽度和半值宽度表示掺杂剂比例的变化。 应当注意，从0.35至0.45的掺杂剂比率的掺杂剂比x和积分宽度之间的直接比例关系，通过XRD获得的积分宽度导出为0.35至0.45的掺杂剂比为0.10至0.30 ，并且半宽度类似地导出为0.10至0.30。

    Aptamer against IL-17 and use thereof
    7.
    发明授权
    Aptamer against IL-17 and use thereof 有权
    针对IL-17的抗体及其用途

    公开(公告)号：US08440801B2

    公开(公告)日：2013-05-14

    申请号：US13003240

    申请日：2009-07-14

    申请人： Yoshikazu Nakamura ,  Shoji Ohuchi ,  Akira Ishiguro

    发明人： Yoshikazu Nakamura ,  Shoji Ohuchi ,  Akira Ishiguro

    IPC分类号： C07H21/02 ,  C12Q1/68 ,  A61K48/00

    CPC分类号： G01N33/6869 ,  A61K31/7105 ,  A61K47/549 ,  C12N15/115 ,  C12N2310/16 ,  G01N2333/54

    摘要： The invention provides an aptamer possessing an inhibitory activity against IL-17, as well as a complex comprising an aptamer possessing a binding activity or inhibitory activity against IL-17 and a functional substance (for example, affinity substances, substances for labeling, enzymes, drug delivery vehicles, drugs and the like). The invention also provides a pharmaceutical drug, cell migration inhibitor, diagnostic reagent, detection probe, carrier, labeling agent, and the like comprising the aforementioned aptamer or complex, and methods of detecting and purifying IL-17 by using the aforementioned aptamer or complex.

    摘要翻译： 本发明提供了具有对IL-17的抑制活性的适体，以及包含对IL-17具有结合活性或抑制活性的适体的复合物和功能性物质（例如亲和性物质，标记物质，酶， 药物输送车辆，药物等）。 本发明还提供包含上述适体或复合物的药物，细胞迁移抑制剂，诊断试剂，检测探针，载体，标记试剂等，以及通过使用上述适体或复合物检测和纯化IL-17的方法。

    Method of manufacturing a thin-film magnetic device
    8.
    发明授权
    Method of manufacturing a thin-film magnetic device 失效
    制造薄膜磁性装置的方法

    公开(公告)号：US6042899A

    公开(公告)日：2000-03-28

    申请号：US172851

    申请日：1998-10-15

    申请人： Akira Ishiguro

    发明人： Akira Ishiguro

    IPC分类号： H01F41/22 ,  H01F10/26 ,  H01F41/14 ,  H01F41/34 ,  H01L23/522 ,  H01F1/00

    CPC分类号： H01F10/26 ,  H01F41/14 ,  H01F41/34 ,  H01L23/5227 ,  H01L2924/0002

    摘要： In a method of manufacturing a thin-film magnetic device having a magnetic film provided with uniaxial magnetic anisotropy, the magnetic film, which is formed on a Si wafer, is patterned, before it is heat-treated in a magnetic field, in such a manner that the length of the magnetic film in a direction parallel to that of the magnetic field is greater than the length of the magnetic film in a direction perpendicular thereto. The magnetic film is divided into band-like magnetic films, and the band-like magnetic films are heat-treated in the magnetic field and each provided with uniaxial magnetic anisotropy. The band-like magnetic films are patterned and each divided again into magnetic films of a chip size. Thus, a crack or a blister can be prevented from occurring on the magnetic film, and the magnetic characteristics of the magnetic film can be prevented from deteriorating.

    摘要翻译： 在制造具有单轴磁各向异性的磁性膜的薄膜磁性装置的制造方法中，将形成在Si晶片上的磁性膜在磁场中进行热处理之前被图案化， 磁性膜在与磁场平行的方向上的长度大于磁性膜在与其垂直的方向上的长度的方式。 将磁性膜分为带状磁性膜，带状磁性膜在磁场中进行热处理，各自具有单轴磁各向异性。 带状磁性膜被图案化，并且再次分成芯片尺寸的磁性膜。 因此，可以防止在磁性膜上发生裂纹或起泡，并且可以防止磁性膜的磁特性劣化。

    Aptamer to FGF2 and use thereof
    10.
    发明授权
    Aptamer to FGF2 and use thereof 失效
    适应FGF2及其用途

    公开(公告)号：US08772259B2

    公开(公告)日：2014-07-08

    申请号：US13578023

    申请日：2011-02-10

    申请人： Yoshikazu Nakamura ,  Akira Ishiguro ,  Maiko Sakamoto

    发明人： Yoshikazu Nakamura ,  Akira Ishiguro ,  Maiko Sakamoto

    IPC分类号： C12N15/11 ,  C12Q1/68 ,  C12N15/115

    CPC分类号： C12N15/115 ,  A61K31/7105 ,  A61K31/712 ,  C12N2310/16 ,  C12N2310/322 ,  C12N2310/344

    摘要： Provided are an aptamer having an inhibitory activity on FGF2; a complex containing an aptamer having a binding activity or an inhibitory activity on FGF2, and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery vehicle, or drug and the like); a medicament, diagnostic reagent or label containing an aptamer having a binding activity or an inhibitory activity on FGF2, or a complex containing said aptamer and a functional substance; and the like.

    摘要翻译： 提供对FGF2具有抑制活性的适体; 含有对FGF2具有结合活性或抑制活性的适体的复合物和功能性物质（例如亲和性物质，标记物质，酶，药物输送载体，药物等）; 包含对FGF2具有结合活性或抑制活性的适体的药物，诊断试剂或标记，或含有所述适体和功能性物质的复合物; 等等。